Virpax Pharmaceuticals SaidOn March 15, Got Letter From Nasdaq That Co Has Regained Compliance With Listing Rule 5550(A)(2)
Virpax Pharmicals表示,3月15日收到納斯達克的來信,稱該公司已恢復遵守上市規則5550(A)(2)
Virpax Pharmaceuticals SaidOn March 15, Got Letter From Nasdaq That Co Has Regained Compliance With Listing Rule 5550(A)(2)
Virpax Pharmicals表示,3月15日收到納斯達克的來信,稱該公司已恢復遵守上市規則5550(A)(2)
使用瀏覽器的分享功能,分享給你的好友吧